NASDAQ:CNSP CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis $1.30 -0.02 (-1.52%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.21 -0.09 (-6.92%) As of 03/28/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CNS Pharmaceuticals Stock (NASDAQ:CNSP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CNS Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.21▼$1.3850-Day Range$1.30▼$7.1352-Week Range$1.21▼$965.00Volume161,488 shsAverage Volume276,800 shsMarket Capitalization$1.50 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingBuy Company OverviewCNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Read More… Remove Ads CNS Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreCNSP MarketRank™: CNS Pharmaceuticals scored higher than 37% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCNS Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCNS Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about CNS Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CNS Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CNS Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about CNS Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.17% of the float of CNS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CNS Pharmaceuticals has recently decreased by 32.92%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCNS Pharmaceuticals does not currently pay a dividend.Dividend GrowthCNS Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.17% of the float of CNS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CNS Pharmaceuticals has recently decreased by 32.92%, indicating that investor sentiment is improving significantly. News and Social Media1.8 / 5News Sentiment0.22 News SentimentCNS Pharmaceuticals has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for CNS Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 13 people have searched for CNSP on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added CNS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CNS Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.07% of the stock of CNS Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 14.02% of the stock of CNS Pharmaceuticals is held by institutions.Read more about CNS Pharmaceuticals' insider trading history. Receive CNSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CNS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CNSP Stock News HeadlinesCNS Pharmaceuticals' (CNSP) Hold Rating Reaffirmed at Maxim GroupMarch 27 at 2:55 AM | americanbankingnews.comCNS Pharmaceuticals announces primary analysis of berubicin in GBMMarch 26 at 10:29 AM | markets.businessinsider.comA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....March 29, 2025 | Banyan Hill Publishing (Ad)CNS Pharmaceuticals down 55% after Berubicin doesn’t show OS superiority in GBMMarch 26 at 10:29 AM | markets.businessinsider.comMaxim Group Downgrades CNS Pharmaceuticals (CNSP)March 26 at 5:29 AM | msn.comCNS Pharmaceuticals (NASDAQ: CNSP) Reports Phase 2 Results for Berubicin in Glioblastoma TrialMarch 26 at 12:28 AM | theglobeandmail.comCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma MultiformeMarch 25, 2025 | finanznachrichten.deCNS Pharma Shares Sink After Berubicin Trial for Brain Cancer Misses Survival EndpointMarch 25, 2025 | marketwatch.comSee More Headlines CNSP Stock Analysis - Frequently Asked Questions How have CNSP shares performed this year? CNS Pharmaceuticals' stock was trading at $6.02 at the beginning of 2025. Since then, CNSP shares have decreased by 78.4% and is now trading at $1.30. View the best growth stocks for 2025 here. How were CNS Pharmaceuticals' earnings last quarter? CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) announced its earnings results on Tuesday, November, 14th. The company reported ($2,700.00) EPS for the quarter, beating analysts' consensus estimates of ($4,325.00) by $1,625.00. When did CNS Pharmaceuticals' stock split? CNS Pharmaceuticals's stock reverse split before market open on Friday, February 21st 2025. The 1-50 reverse split was announced on Wednesday, February 19th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did CNS Pharmaceuticals IPO? CNS Pharmaceuticals (CNSP) raised $9 million in an initial public offering (IPO) on Friday, November 8th 2019. The company issued 2,100,000 shares at a price of $4.00-$5.00 per share. Benchmark acted as the underwriter for the IPO. Who are CNS Pharmaceuticals' major shareholders? Top institutional shareholders of CNS Pharmaceuticals include Jane Street Group LLC (0.73%), Geode Capital Management LLC (0.67%), Citadel Advisors LLC (0.56%) and XTX Topco Ltd (0.51%). Insiders that own company stock include Waldemar Priebe, John M Climaco, Christopher Downs and Jerzy Gumulka. View institutional ownership trends. How do I buy shares of CNS Pharmaceuticals? Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CNS Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that CNS Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO) and General Electric (GE). Company Calendar Last Earnings11/14/2023Today3/28/2025Next Earnings (Estimated)4/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNSP CIK1729427 Webwww.cnspharma.com Phone800-946-9185FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$25.00 High Stock Price Target$25.00 Low Stock Price Target$25.00 Potential Upside/Downside+1,823.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3,748.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,850,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-515.32% Debt Debt-to-Equity RatioN/A Current Ratio1.82 Quick Ratio1.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($35.66) per share Price / Book-0.04Miscellaneous Outstanding Shares1,150,000Free Float57,447,000Market Cap$1.50 million OptionableNot Optionable Beta2.65 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CNSP) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.